166 related articles for article (PubMed ID: 38413410)
1. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.
Streuer A; Jann JC; Boch T; Mossner M; Riabov V; Schmitt N; Altrock E; Xu Q; Demmerle M; Nowak V; Oblaender J; Palme I; Weimer N; Rapp F; Metzgeroth G; Hecht A; Höger T; Merz C; Hofmann WK; Nolte F; Nowak D
Ann Hematol; 2024 Apr; 103(4):1221-1233. PubMed ID: 38413410
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
3. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.
Radujkovic A; Boch T; Nolte F; Nowak D; Kunz C; Gieffers A; Müller-Tidow C; Dreger P; Hofmann WK; Luft T
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33302451
[TBL] [Abstract][Full Text] [Related]
4. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
Raimbault A; Pierre-Eugene C; Rouquette A; Deudon C; Willems L; Chapuis N; Mathis S; Kunz C; Fricke H; Kosmider O; Bardet V; Fontenay M;
Oncotarget; 2016 Mar; 7(12):14898-911. PubMed ID: 26910909
[TBL] [Abstract][Full Text] [Related]
5. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Chesnais V; Renneville A; Toma A; Lambert J; Passet M; Dumont F; Chevret S; Lejeune J; Raimbault A; Stamatoullas A; Rose C; Beyne-Rauzy O; Delaunay J; Solary E; Fenaux P; Dreyfus F; Preudhomme C; Kosmider O; Fontenay M;
Blood; 2016 Feb; 127(6):749-60. PubMed ID: 26626993
[TBL] [Abstract][Full Text] [Related]
6. Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms.
Zaidi SDEZ; Fatima Zaidi SM; Rangwala BS
Ann Hematol; 2024 Jun; 103(6):2163-2164. PubMed ID: 38652243
[No Abstract] [Full Text] [Related]
7. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
Stosch JM; Heumüller A; Niemöller C; Bleul S; Rothenberg-Thurley M; Riba J; Renz N; Szarc Vel Szic K; Pfeifer D; Follo M; Pahl HL; Zimmermann S; Duyster J; Wehrle J; Lübbert M; Metzeler KH; Claus R; Becker H
Br J Haematol; 2018 Sep; 182(6):830-842. PubMed ID: 29974943
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
9. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.
Mundle SD; Mativi BY; Bagai K; Feldman G; Cheema P; Gautam U; Reza S; Cartlidge JD; Venugopal P; Shetty V; Gregory SA; Robin E; Rifkin S; Shah R; Raza A
Int J Hematol; 1999 Aug; 70(2):83-90. PubMed ID: 10497846
[TBL] [Abstract][Full Text] [Related]
11. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
12. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
Cull AH; Rauh MJ
J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
[TBL] [Abstract][Full Text] [Related]
13. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies.
Krendyukov A; Gieffers C
Cancer Manag Res; 2019; 11():8095-8100. PubMed ID: 31564969
[TBL] [Abstract][Full Text] [Related]
14. Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow.
Tamura S; Kanamaru A; Takemoto Y; Kakishita E; Nagai K
Br J Haematol; 1993 Jun; 84(2):219-26. PubMed ID: 8398821
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in myelodysplastic syndromes: ASH 2003 review.
Candoni A; Silvestri F; Buonamici S; Li D; Reddy P; Galili N; Nucifora G; Raza A
Semin Hematol; 2004 Apr; 41(2 Suppl 4):13-20. PubMed ID: 15190511
[TBL] [Abstract][Full Text] [Related]
16. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of clonal evolution in myelodysplastic syndromes.
Makishima H; Yoshizato T; Yoshida K; Sekeres MA; Radivoyevitch T; Suzuki H; Przychodzen B; Nagata Y; Meggendorfer M; Sanada M; Okuno Y; Hirsch C; Kuzmanovic T; Sato Y; Sato-Otsubo A; LaFramboise T; Hosono N; Shiraishi Y; Chiba K; Haferlach C; Kern W; Tanaka H; Shiozawa Y; Gómez-Seguí I; Husseinzadeh HD; Thota S; Guinta KM; Dienes B; Nakamaki T; Miyawaki S; Saunthararajah Y; Chiba S; Miyano S; Shih LY; Haferlach T; Ogawa S; Maciejewski JP
Nat Genet; 2017 Feb; 49(2):204-212. PubMed ID: 27992414
[TBL] [Abstract][Full Text] [Related]
18. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
20. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
